Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203931 · ClinicalTrials.gov registry record · Phase 2
Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00203931 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 55 participants.
The verdict
NCT00203931, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of the study is to determine in patients with Non Small Cell Lung Cancer refractory to previous chemotherapy whether concomitant treatment with cetuximab and pemetrexed improves progression-free survival compared with cetuximab monotherapy.
Interventions
- DRUG Pemetrexed
- DRUG Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2005-03 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203931
The ClinicalTrials.gov registry entry for NCT00203931 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pemetrexed is the first listed.
NCT00203931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00203931 about?
NCT00203931 is a clinical study titled "Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer". The purpose of the study is to determine in patients with Non Small Cell Lung Cancer refractory to previous chemotherapy whether concomitant treatment with cetuximab and pemetrexed improves progression-free survival compared with cetuximab monotherapy.
What is the current status of trial NCT00203931?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2005-03. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00203931?
The interventions under investigation include: Pemetrexed (DRUG), Cetuximab (DRUG).
Who is sponsoring clinical trial NCT00203931?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.